GlassScriptPhysician profile
James O Alexander
NPI 1114094851
$10,882.03
in general payments reported to CMS, 2019-2025
43 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,623 · 2020: $2,346 · 2021: $2,352 · 2022: $40.84 · 2023: $652 · 2024: $1,637 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,257.39 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,169.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,085.17 | 2019-2025 | |
| Novo Nordisk INC | $1,035.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,026.13 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $929.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $663.80 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $516.98 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $308.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $271.03 | 2019-2023 | Verquvo |
| Esperion Therapeutics, INC. | $246.26 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $239.73 | 2019-2025 | |
| Allergan, INC. | $198.97 | 2020 | |
| Sumitomo Pharma America, INC. | $169.11 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $128.19 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.